In 2014, Marie obtained her Master’s degree in Cellular Engineering at Université de Lorraine (Nancy) after a seven-months internship at Promethera Biosciences (Mont-Saint-Guibert, Belgium) where she investigated senescence of liver progenitor cells.

She worked as an engineer in the field of oncology at Institut de Biologie de Lille (UMR8161, 2015-2016) and developped microfluidic cell culture in the BioMEMS team of Institut d’Électronique, de Microélectronique et de Nanotechnologie (IEMN, UMR8520, Université de Lille, 2016-2017).

According to a report issued by the Tufts Center for the Study of Drug Development, the costs associated with bringing a novel drug to market exceed $2.5 billion per successful compound. Drug developers search for other innovation systems which are more relevant with physiological and clinical predictability. They deplore the Gap between Conventional 2D Cell Cultures and In Vivo Animal Models. New technologies, as 3D culture including micro-environnement as proposed by Celenys company, our partner for 3D culture, or to go further as bioprinting or as organ-on-a-chip with microfluidic system are really nice technologies to fill the gap between both systems or to replace 2D culture experiments.

“Historically, drug discovery research has relied on two-dimensional in vitro assays (that is, cell monolayers cultured on plastic substrata) and in vivo animal models. Although these systems still predominate, drug developers are beginning to doubt whether the familiar assays and animal models are adequate with respect to physiological relevance and clinical predictability. And drug developers are losing patience with persistently dismal rates of translation.”

Source: 3D Cell Culture Draws Drug Developers’ Interest | GEN Magazine Articles | GEN

by multiplexing assays on have many advantages to find more efficient new drugs for treatment. Progress in the IT part, on softwares, on the uses on big data and in the machine on speed and sensitivity allow to do multiplexing assays in HCS . This article shows us another example on this multiplexing assays on tumour and .

The high-throughput assay procedures use ready-made plates, open-source software and are compatible with standard plate readers, therefore offering high predictive power with substantial savings in time and money.

Curated from www.plosone.org

%d bloggers like this: